News

Novo's new CEO faces sceptical investors with Wegovy US sales in focus
Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of ...
The Motley Fool2mon
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in ...
Novo Nordisk has an estimated 62% market share of the GLP-1 agonist market, with archrival Eli Lilly accounting for another 35%. Investors are looking ahead to next-generation drugs that could ...
The New York Times2mon
Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs
A version of this article appears in print on May 17, 2025, Section B, Page 5 of the New York edition with the headline: Novo Nordisk, Its Stock Falling and Competition Rising, Will Replace Its C ...
Novo Falls by Record as Wegovy Slumps and Insider Named CEO
Novo Nordisk A/S named its head of international operations as chief executive officer after slumping weight-loss drug sales led to a profit warning that wiped $93 billion off its market value.